These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 26568411)

  • 1. Discovery of Oral VEGFR-2 Inhibitors with Prolonged Ocular Retention That Are Efficacious in Models of Wet Age-Related Macular Degeneration.
    Meredith EL; Mainolfi N; Poor S; Qiu Y; Miranda K; Powers J; Liu D; Ma F; Solovay C; Rao C; Johnson L; Ji N; Artman G; Hardegger L; Hanks S; Shen S; Woolfenden A; Fassbender E; Sivak JM; Zhang Y; Long D; Cepeda R; Liu F; Hosagrahara VP; Lee W; Tarsa P; Anderson K; Elliott J; Jaffee B
    J Med Chem; 2015 Dec; 58(23):9273-86. PubMed ID: 26568411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Discovery of N-(1-Methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6- ((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide (Acrizanib), a VEGFR-2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration.
    Adams CM; Anderson K; Artman G; Bizec JC; Cepeda R; Elliott J; Fassbender E; Ghosh M; Hanks S; Hardegger LA; Hosagrahara VP; Jaffee B; Jendza K; Ji N; Johnson L; Lee W; Liu D; Liu F; Long D; Ma F; Mainolfi N; Meredith EL; Miranda K; Peng Y; Poor S; Powers J; Qiu Y; Rao C; Shen S; Sivak JM; Solovay C; Tarsa P; Woolfenden A; Zhang C; Zhang Y
    J Med Chem; 2018 Feb; 61(4):1622-1635. PubMed ID: 29400470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between choroidal thickness and the response to intravitreal ranibizumab injection in age-related macular degeneration.
    Shin JY; Kwon KY; Byeon SH
    Acta Ophthalmol; 2015 Sep; 93(6):524-32. PubMed ID: 25581639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-vascular endothelial growth factor injection technique for recurrent exudative macular degeneration in a telescope-implanted eye.
    Joondeph BC
    Retin Cases Brief Rep; 2014; 8(4):342-4. PubMed ID: 25372544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Axitinib inhibits retinal and choroidal neovascularization in in vitro and in vivo models.
    Giddabasappa A; Lalwani K; Norberg R; Gukasyan HJ; Paterson D; Schachar RA; Rittenhouse K; Klamerus K; Mosyak L; Eswaraka J
    Exp Eye Res; 2016 Apr; 145():373-379. PubMed ID: 26927930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of retinal and choroidal neovascularization by a novel KDR kinase inhibitor.
    Kinose F; Roscilli G; Lamartina S; Anderson KD; Bonelli F; Spence SG; Ciliberto G; Vogt TF; Holder DJ; Toniatti C; Thut CJ
    Mol Vis; 2005 May; 11():366-73. PubMed ID: 15951738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Anti VEGF therapy in different forms of wet ARMD].
    Panait OM
    Oftalmologia; 2011; 55(4):17-9. PubMed ID: 22642131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic beta-blockers may reduce the need for repeated intravitreal injections in patients with wet age-related macular degeneration treated by bevacizumab.
    Montero JA; Ruiz-Moreno JM; Sanchis-Merino E; Perez-Martin S
    Retina; 2013 Mar; 33(3):508-12. PubMed ID: 23099497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing.
    Heier JS; Boyer D; Nguyen QD; Marcus D; Roth DB; Yancopoulos G; Stahl N; Ingerman A; Vitti R; Berliner AJ; Yang K; Brown DM;
    Ophthalmology; 2011 Jun; 118(6):1098-106. PubMed ID: 21640258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
    Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
    J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel CCR3 Antagonists Are Effective Mono- and Combination Inhibitors of Choroidal Neovascular Growth and Vascular Permeability.
    Nagai N; Ju M; Izumi-Nagai K; Robbie SJ; Bainbridge JW; Gale DC; Pierre E; Krauss AH; Adamson P; Shima DT; Ng YS
    Am J Pathol; 2015 Sep; 185(9):2534-49. PubMed ID: 26188133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumab.
    Muether PS; Hermann MM; Viebahn U; Kirchhof B; Fauser S
    Ophthalmology; 2012 Oct; 119(10):2082-6. PubMed ID: 22920670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal ranibizumab for predominantly hemorrhagic choroidal neovascularization in age-related macular degeneration.
    Lazzeri S; Figus M; Sartini MS; Scarinci F; Casini G; Guidi G; Cupo G; Cacciamani A; Fasanella V; Agnifili L; Piaggi P; Varano M; Ripandelli G; Nardi M; Parravano M
    Ophthalmologica; 2015; 233(2):74-81. PubMed ID: 25662794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical evaluation of pazopanib eye drops versus ranibizumab intravitreal injections in subjects with neovascular age-related macular degeneration.
    Csaky KG; Dugel PU; Pierce AJ; Fries MA; Kelly DS; Danis RP; Wurzelmann JI; Xu CF; Hossain M; Trivedi T
    Ophthalmology; 2015 Mar; 122(3):579-88. PubMed ID: 25432081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-angiogenic effects of the receptor tyrosine kinase inhibitor, pazopanib, on choroidal neovascularization in rats.
    Yafai Y; Yang XM; Niemeyer M; Nishiwaki A; Lange J; Wiedemann P; King AG; Yasukawa T; Eichler W
    Eur J Pharmacol; 2011 Sep; 666(1-3):12-8. PubMed ID: 21620822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exacerbation of choroidal and retinal pigment epithelial atrophy after anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration.
    Young M; Chui L; Fallah N; Or C; Merkur AB; Kirker AW; Albiani DA; Forooghian F
    Retina; 2014 Jul; 34(7):1308-15. PubMed ID: 24451923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
    Heier JS; Brown DM; Chong V; Korobelnik JF; Kaiser PK; Nguyen QD; Kirchhof B; Ho A; Ogura Y; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Soo Y; Anderesi M; Groetzbach G; Sommerauer B; Sandbrink R; Simader C; Schmidt-Erfurth U;
    Ophthalmology; 2012 Dec; 119(12):2537-48. PubMed ID: 23084240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of changes in choroidal neovascularization secondary to age-related macular degeneration after anti-VEGF therapy using spectral domain optical coherence tomography.
    You JY; Chung H; Kim HC
    Curr Eye Res; 2012 May; 37(5):438-45. PubMed ID: 22510011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognosti implications of pigment epithelial detachment in bevacizumab (avastin)-treated eyes with age-related macular degeneration and choroidal neovascularization.
    Freeman WR; Kozak I; Yuson RM; Nigam N; Cheng L; Mojana F
    Retina; 2011 Oct; 31(9):1812-8. PubMed ID: 21866073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VEGFR2 Trafficking by KIF13B Is a Novel Therapeutic Target for Wet Age-Related Macular Degeneration.
    Waters SB; Zhou C; Nguyen T; Zelkha R; Lee H; Kazlauskas A; Rosenblatt MI; Malik AB; Yamada KH
    Invest Ophthalmol Vis Sci; 2021 Feb; 62(2):5. PubMed ID: 33533881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.